IMM Immupharma Plc

 

TIDMIMM 
 
 
Immupharma PLC 
21 September 2009 
 
? 
 
 
 
 
 
 
 
 
+------------------------------------+------------------------------------+ 
| For Immediate Release              |                  21 September 2009 | 
+------------------------------------+------------------------------------+ 
 
 
 
 
 
 
ImmuPharma PLC 
 
 
IMMUPHARMA TO PRESENT AT 8TH ANNUAL BIO INVESTOR FORUM 
 
 
ImmuPharma PLC (LSE:IMM), the drug discovery and development group announces 
that Dimitri Dimitriou, Chief Executive Officer will be presenting at the 2009 
BIO Investor Forum. Hosted by the Biotechnology Industry Organisation (BIO), the 
8th Annual BIO Investor Forum will take place on October 28-29 at the Palace 
Hotel in San Francisco, California. 
 
 
- Ends - 
 
 
For further information please contact: 
 
 
+----------------------------------------------------+-------------------+ 
| ImmuPharma PLC:                                    |  +44 20 7152 4080 | 
+----------------------------------------------------+-------------------+ 
| Dimitri Dimitriou, Chief Executive Officer         |                   | 
+----------------------------------------------------+-------------------+ 
|                                                    |                   | 
+----------------------------------------------------+-------------------+ 
| Buchanan Communications:                           |  +44 20 7466 5000 | 
+----------------------------------------------------+-------------------+ 
| Lisa Baderoon                                      |                   | 
+----------------------------------------------------+-------------------+ 
|                                                    |                   | 
+----------------------------------------------------+-------------------+ 
 
 
 
 
Notes to Editors 
 
 
About ImmuPharma PLC 
 
 
ImmuPharma is a drug discovery and development group with its key operations in 
London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company 
aims to develop novel drugs to treat serious medical conditions for which there 
is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) 
Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) 
Inflammatory and Allergic disorders. 
 
 
Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, 
life-threatening autoimmune disease, was licensed to Cephalon, Inc in a 
transaction worth up to $500m in milestone payments in addition to significant 
royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m 
post year end in Q1 2009 
The company also has a strong proprietary and collaborative drug development 
pipeline. 
 
 
About The Bio Investor Forum 
 
 
The 8th Annual BIO Investor Forum is an international conference featuring 
late-stage private and emerging public companies. This year's BIO Investor Forum 
will feature more than 110 presentations by private and publicly traded 
companies, venture philanthropy organizations, and patient advocacy groups; as 
well as Therapeutic Workshops(TM) and Business Roundtables with distinguished 
clinicians, investigators, and investors. Experts hand-selected to speak at this 
conference will focus on current biotechnology pipeline innovation, and the 
latest trends in clinical strategy, capital access and creative funding 
techniques. The Eighth Annual BIO Investor Forum will include healthcare venture 
and private equity investors, buy-side investors, and research analysts as well 
as business development executives from leading global pharmaceutical and mature 
biotechnology companies. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRASEDSAFSUSEIU 
 

Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024